Preclinical evaluation of multiple species of PEGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuria
about
Phenylketonuria: a review of current and future treatmentsPhenylketonuria: translating research into novel therapiesCrystal structure of Bacillus fastidious uricase reveals an unexpected folding of the C-terminus residues crucial for thermostability under physiological conditionsGenetically engineered probiotic for the treatment of phenylketonuria (PKU); assessment of a novel treatment in vitro and in the PAHenu2 mouse model of PKUComparison of adeno-associated virus pseudotype 1, 2, and 8 vectors administered by intramuscular injection in the treatment of murine phenylketonuriaNovel pharmacological chaperones that correct phenylketonuria in mice.Phenylalanine hydroxylase misfolding and pharmacological chaperones.Evaluation of orally administered PEGylated phenylalanine ammonia lyase in mice for the treatment of Phenylketonuria.Up to date knowledge on different treatment strategies for phenylketonuria.Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trialUricases as therapeutic agents to treat refractory gout: Current states and future directions.Fungal and Plant Phenylalanine Ammonia-lyaseFormulation and PEGylation optimization of the therapeutic PEGylated phenylalanine ammonia lyase for the treatment of phenylketonuriaReassessment of phenylalanine tolerance in adults with phenylketonuria is needed as body mass changes.Converting an injectable protein therapeutic into an oral form: phenylalanine ammonia lyase for phenylketonuria.Sapropterin dihydrochloride for the treatment of hyperphenylalaninemias.Improving the stability and activity of oral therapeutic enzymes-recent advances and perspectives.Clinical therapeutics for phenylketonuria.Cloning, expression and characterization of phenylalanine ammonia-lyase from Rhodotorula glutinis.Reduction of L-phenylalanine in protein hydrolysates using L-phenylalanine ammonia-lyase from Rhodosporidium toruloides.Mannose 6-phosphate conjugation is not sufficient to allow induction of immune tolerance to phenylalanine ammonia-lyase in dogs.Biochemical Evaluation of Phenylalanine Ammonia Lyase from Endemic Plant Cyathobasis fruticulosa (Bunge) Aellen. for the Dietary Treatment of Phenylketonuria.Engineering and kinetic stabilization of the therapeutic enzyme Anabeana variabilis phenylalanine ammonia lyase."Bio"-macromolecules: polymer-protein conjugates as emerging scaffolds for therapeutics.Maternal Phenylketonuria syndrome: Studies in mice suggest a potential approach to a continuing problem.Dietary intervention in the management of phenylketonuria: current perspectives.Descriptive and hedonic analyses of low-Phe food formulations containing corn (Zea mays) seedling roots: toward development of a dietary supplement for individuals with phenylketonuria.Alternative therapies to address the unmet medical needs of patients with phenylketonuria.Phenylalanine ammonia-lyase, a key component used for phenylpropanoids production by metabolic engineering
P2860
Q26770291-CB4512E3-D1F2-4C9F-AC22-A4749ED7A598Q27015749-FBD92368-2F23-4B64-88D5-69C8DDACC5A2Q27698539-9086675D-948A-4A2B-A2A7-C8235ED3DD22Q33698843-83131387-8E14-4C01-BFBF-156BF3A76E26Q33832790-2FF82035-F7C0-41A2-BB79-B3B92F8702FAQ34127906-FE9BCA33-B21C-40E4-B639-64A83BEC1429Q34556955-0DD00987-A877-46C2-A6C3-3947C62F198EQ35490408-A659E32C-AE76-4953-B742-0532D581591CQ35623929-F9314CD7-419A-4966-B003-8382DA72FF52Q35660020-8EA0659B-3E87-4414-8AAD-C9CE645CB72CQ36002499-D5EEA4FA-C465-42C6-97B3-F8435A91318CQ36064058-651F081C-9D81-4A54-84E7-9515ED6E818DQ36304253-3AD5B2E8-1AD8-4333-A677-C50F2477D2ADQ37441175-27CE4FDD-E679-40C1-8D4F-E4DC740D8F7CQ37480507-F167F1F9-F920-4ADD-8A4C-BDACCA514916Q38109232-35BDD597-3936-4401-94AA-97F69D2CCD85Q38159436-0B8207DB-5736-40C9-B2B7-91C984AE750DQ38383086-97A5B14A-A690-43A5-AB2D-052DB508E083Q39481386-9EFB24A9-1B27-4369-B1AB-79B5A26BA59FQ41513897-D9AA9676-947C-4F55-845C-418900274F0BQ42257752-AB8C5E55-201A-4120-951F-E4C4C74D24D2Q42354366-A5EB6FA9-F08B-4EA7-B235-BF419014EBE3Q45010181-82870BEB-E2D3-4CB5-B009-2A3FFC48EE76Q46335892-3EA0BCC5-1DE0-4C42-BF15-CDB055AE86F7Q47248016-92E244DE-B081-44DC-96E2-CB7706D61475Q49500552-F461487C-4D3F-4DE1-935F-E32C969B3811Q50218729-62B1ED09-EE92-44CB-B926-D20A9F55EB6AQ54273999-32990B32-DE42-4C95-938F-43E3E648214DQ56336398-10BE987E-764B-4670-9048-F46164B37573
P2860
Preclinical evaluation of multiple species of PEGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuria
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Preclinical evaluation of mult ...... e treatment of phenylketonuria
@en
Preclinical evaluation of mult ...... treatment of phenylketonuria.
@nl
type
label
Preclinical evaluation of mult ...... e treatment of phenylketonuria
@en
Preclinical evaluation of mult ...... treatment of phenylketonuria.
@nl
prefLabel
Preclinical evaluation of mult ...... e treatment of phenylketonuria
@en
Preclinical evaluation of mult ...... treatment of phenylketonuria.
@nl
P2093
P2860
P356
P1476
Preclinical evaluation of mult ...... e treatment of phenylketonuria
@en
P2093
Alejandra Gámez
Amy Lambert
Carroll Henschell
Christineh N Sarkissian
Jeffrey F Lemontt
Laurie Tsuruda
Marilyse Charbonneau
Michael Vellard
P2860
P304
20894-20899
P356
10.1073/PNAS.0808421105
P407
P577
2008-12-18T00:00:00Z